8.72
price down icon7.43%   -0.70
after-market Dopo l'orario di chiusura: 8.56 -0.16 -1.83%
loading
Precedente Chiudi:
$9.42
Aprire:
$9
Volume 24 ore:
1.90M
Relative Volume:
1.57
Capitalizzazione di mercato:
$1.12B
Reddito:
$628.25M
Utile/perdita netta:
$-78.55M
Rapporto P/E:
-14.06
EPS:
-0.62
Flusso di cassa netto:
$-29.73M
1 W Prestazione:
-8.02%
1M Prestazione:
-8.98%
6M Prestazione:
-38.24%
1 anno Prestazione:
-41.36%
Intervallo 1D:
Value
$8.69
$9.09
Intervallo di 1 settimana:
Value
$8.69
$9.688
Portata 52W:
Value
$8.69
$19.11

Neogenomics Inc Stock (NEO) Company Profile

Name
Nome
Neogenomics Inc
Name
Telefono
(239) 768-0600
Name
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Name
Dipendente
0
Name
Cinguettio
@NeoGenomics
Name
Prossima data di guadagno
2025-02-18
Name
Ultimi documenti SEC
Name
NEO's Discussions on Twitter

Confronta NEO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
NEO
Neogenomics Inc
8.72 1.12B 628.25M -78.55M -29.73M -0.62
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
470.03 177.32B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
197.90 141.59B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
410.76 33.29B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
109.67 31.28B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
167.69 29.57B 15.41B 1.37B 2.11B 7.50

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-13 Downgrade The Benchmark Company Buy → Hold
2024-12-10 Iniziato Jefferies Buy
2024-05-01 Ripresa Craig Hallum Buy
2023-12-29 Reiterato BTIG Research Buy
2023-08-21 Aggiornamento Stephens Equal-Weight → Overweight
2023-05-16 Downgrade Raymond James Outperform → Mkt Perform
2023-05-09 Aggiornamento BTIG Research Neutral → Buy
2023-02-24 Aggiornamento The Benchmark Company Hold → Buy
2023-02-01 Aggiornamento Needham Hold → Buy
2022-08-26 Downgrade The Benchmark Company Buy → Hold
2022-08-22 Downgrade Needham Buy → Hold
2022-06-03 Iniziato Piper Sandler Overweight
2022-03-29 Downgrade BofA Securities Buy → Neutral
2022-03-29 Downgrade Stephens Overweight → Equal-Weight
2022-01-18 Ripresa Stephens Overweight
2021-12-16 Iniziato Cowen Outperform
2021-11-05 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-10-14 Aggiornamento Raymond James Mkt Perform → Outperform
2021-06-03 Iniziato Goldman Buy
2021-02-25 Ripresa Needham Buy
2021-02-25 Downgrade Raymond James Outperform → Mkt Perform
2021-01-28 Iniziato Truist Buy
2020-12-11 Ripresa BTIG Research Buy
2020-10-28 Reiterato Needham Buy
2020-09-09 Iniziato Morgan Stanley Overweight
2020-08-28 Iniziato Guggenheim Buy
2020-07-29 Reiterato Needham Buy
2020-06-25 Iniziato BofA/Merrill Buy
2020-04-21 Ripresa Stephens Overweight
2020-03-02 Ripresa Craig Hallum Buy
2020-02-28 Aggiornamento First Analysis Sec Outperform → Strong Buy
2020-01-23 Downgrade First Analysis Sec Strong Buy → Outperform
2019-10-30 Reiterato Needham Buy
2019-05-01 Reiterato Needham Buy
2019-03-29 Reiterato Needham Buy
2019-01-03 Iniziato Needham Buy
2018-10-24 Aggiornamento First Analysis Sec Outperform → Strong Buy
2018-08-21 Iniziato Leerink Partners Outperform
2018-05-02 Downgrade First Analysis Sec Overweight → Equal-Weight
2017-09-11 Downgrade BTIG Research Buy → Neutral
2017-08-24 Iniziato Gabelli & Co Buy
2016-12-15 Iniziato Cantor Fitzgerald Overweight
Mostra tutto

Neogenomics Inc Borsa (NEO) Ultime notizie

pulisher
10:00 AM

NeoGenomics stock hits 52-week low at $8.9 amid challenges - Investing.com Australia

10:00 AM
pulisher
05:06 AM

Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) - The Globe and Mail

05:06 AM
pulisher
Apr 02, 2025

NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

NeoGenomics Schedules its First Quarter Earnings Release for April 30, 2019 - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

NeoGenomics announces CEO transition - MSN

Apr 02, 2025
pulisher
Apr 01, 2025

New CEO assumes role at NeoGenomics - Gulfshore Business

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics appoints Tony Zook as CEO - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics, Inc. Announces CEO Changes - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics - BioSpace

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics appoints Tony Zook as CEO By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics Appoints Tony Zook Chief Executive - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics' New CEO Zook Takes Over as Smith Retires - MarketWatch

Apr 01, 2025
pulisher
Apr 01, 2025

Tony Zook Assumes Role As Chief Executive Officer Of Neogenomics - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Diagnostic Leader NeoGenomics Taps 30-Year Veteran to Drive Oncology Testing Growth - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Benchmark maintains Hold on Neogenomics stock, reiterates price target By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 22, 2025

Where are the Opportunities in (NEO) - news.stocktradersdaily.com

Mar 22, 2025
pulisher
Mar 21, 2025

3 Reasons to Sell NEO and 1 Stock to Buy Instead - Yahoo Finance

Mar 21, 2025
pulisher
Mar 19, 2025

Piper Sandler maintains Neogenomics stock with $18 target - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler maintains Neogenomics stock with $18 target By Investing.com - Investing.com UK

Mar 19, 2025
pulisher
Mar 19, 2025

NeoGenomics elevates Warren Stone to President and COO By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

NeoGenomics Promotes Warren Stone to President & COO - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Fort Myers-based NeoGenomics names new COO - Gulfshore Business

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings call transcript: NeoGenomics Q4 2024 results disappoint despite EPS beat - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

NeoGenomics elevates Warren Stone to President and COO - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

NeoGenomics Names Warren Stone President, COO -March 18, 2025 at 08:09 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

NeoGenomics Appoints Warren Stone as President & Chief Operating Officer - Lelezard

Mar 18, 2025
pulisher
Mar 18, 2025

NeoGenomics Appoints Warren Stone As President & Chief Operating Officer -March 18, 2025 at 07:10 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 17, 2025

Commit To Buy NeoGenomics At $8, Earn 19.6% Annualized Using Options - Nasdaq

Mar 17, 2025
pulisher
Mar 15, 2025

NeoGenomics (NASDAQ:NEO) Stock Price Up 7.2%Here's What Happened - MarketBeat

Mar 15, 2025
pulisher
Mar 14, 2025

SBI Securities Co. Ltd. Invests $26,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

NeoGenomics at Barclays Healthcare: Strategic Focus on Innovation - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Bank of New York Mellon Corp Purchases 15,269 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.60 Average Target Price from Analysts - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

(NEO) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 11, 2025
pulisher
Mar 11, 2025

NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Fort Myers-based NeoGenomics expands cancer testing reach with acquisition - News-Press

Mar 11, 2025
pulisher
Mar 11, 2025

Proficio Capital Partners LLC Invests $372,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

BTIG maintains $17 target on Neogenomics stock post-acquisition By Investing.com - Investing.com UK

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics Acquires Pathline -March 10, 2025 at 08:13 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline - BioSpace

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics expands with Pathline acquisition - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics expands with Pathline acquisition By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics Expands Oncology Testing Reach In The Northeast With Acquisition Of Pathline - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Smartleaf Asset Management LLC Has $70,000 Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R) - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 08, 2025

NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St

Mar 08, 2025
pulisher
Mar 07, 2025

NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

NeoGenomics price target lowered to $17 from $18 at BTIG - MSN

Mar 07, 2025
pulisher
Mar 06, 2025

NeoGenomics at TD Cowen Conference: CEO Transition and Growth Plans By Investing.com - Investing.com UK

Mar 06, 2025
pulisher
Mar 04, 2025

NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Truist Financial Corp - Defense World

Mar 04, 2025

Neogenomics Inc Azioni (NEO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$138.71
price down icon 3.14%
diagnostics_research DGX
$170.63
price up icon 1.59%
diagnostics_research LH
$233.46
price down icon 1.23%
diagnostics_research WAT
$345.12
price down icon 4.83%
diagnostics_research MTD
$1,095.24
price down icon 6.59%
diagnostics_research IQV
$167.69
price down icon 3.83%
Capitalizzazione:     |  Volume (24 ore):